Trump administration strikes deal with AbbVie to cut costs of certain drugs
This story raises questions about governance, accountability, and American values.
CNN frames the AbbVie agreement as just another tactical “pact” in a pricing campaign, as if lowering drug costs is mostly a messaging exercise. That misses why many conservatives see this as overdue: patients have been paying inflated prices while the system protects intermediaries and overseas free riders. The real question is whether “Most Favored Nation” pricing changes incentives or just rearranges press releases.
New Republican Times Editorial Board
By Adam Cancryn, Tami Luhby, CNN (CNN) — The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest pact as part of its “Most Favored Nation” pricing initiative.
The deal comes days after the administration inked a deal with Johnson & Johnson, which was announcedThe post Trump administration strikes deal with AbbVie to cut costs of certain drugs appeared first on News-Press NOW.
Original source:
Read at NewspressnowHow We See It
New Republican Times Editorial Board
CNN frames the AbbVie agreement as just another tactical “pact” in a pricing campaign, as if lowering drug costs is mostly a messaging exercise. That misses why many conservatives see this as overdue: patients have been paying inflated prices while the system protects intermediaries and overseas free riders.
The real question is whether “Most Favored Nation” pricing changes incentives or just rearranges press releases. Fairness for American patients means confronting the reality that other countries cap prices and then expect U.S. consumers to subsidize the innovation pipeline. Bringing their prices into the conversation is not radical. It is overdue.
Still, deals should not become a substitute for transparent markets and durable reform. The public deserves public trust that savings are real, not offset by new fees or narrower access. If the goal is institutional stability, it has to outlast one administration and one headline.
Commentary written with AI assistance by the New Republican Times Editorial Board.